THE MOST POWERFUL AMPK ACTIVATOR - AT LEAST 400% MORE EFFECTIVE THAN MOTS-C.
 
ATX-304 (also known as O-304, OS-01, or OS01) is a small molecule pan-AMPK activator with the chemical name 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide, a molecular formula of C₁₆H₁₁Cl₂N₃O₂S, and a molecular weight of 380.2 g/mol.
 It is identified by the CAS number 1261289-04-6 and is available in various forms including liquid, powder, capsules, and as a high-purity research molecule.
 The compound is marketed for laboratory developmental research use only and is not intended for human consumption.
ATX-304 functions as a first-in-class, orally available pan-AMPK activator that increases AMPK activity by suppressing the dephosphorylation of pAMPK at threonine-172, thereby stabilizing its active form even in the presence of high ATP levels.
 This mechanism distinguishes it from indirect AMPK activators like metformin, which rely on changes in cellular energy status.
 The compound promotes glucose uptake in skeletal muscle without requiring insulin, enhances fat oxidation, suppresses fat synthesis, and acts as a mild mitochondrial uncoupler, increasing basal oxygen consumption and calorie burn by approximately 38% in cell models.
 It also promotes autophagy, restores mitochondrial biogenesis markers such as PGC-1α and TFAM, reduces reactive oxygen species (ROS) production, and improves mitochondrial ultrastructure, suggesting a protective role in cellular quality control and energy metabolism.
Preclinical studies have demonstrated that ATX-304 reduces fasting plasma glucose levels, improves insulin sensitivity, and enhances peripheral microcirculatory function, including skin microvascular perfusion, which is relevant to complications of type 2 diabetes.
 In aged mice, chronic treatment with ATX-304 stimulated AMPK-mediated mitochondrial biogenesis, leading to increased cardiac output, improved microvascular perfusion, and greater exercise capacity—effects that mimic the benefits of endurance training without physical exercise.
 It also protects against kidney aging by promoting energy metabolism and autophagy, reduces whole-body fat mass, lowers blood cholesterol levels in models of nonalcoholic steatohepatitis, and reduces β-cell stress in diet-induced obese mice.
In a Phase IIa clinical trial involving patients with type 2 diabetes on metformin, ATX-304 significantly reduced fasting plasma glucose and HOMA-IR, confirming its ability to suppress hepatic gluconeogenesis and enhance skeletal-muscle glucose uptake via AMPK activation.
 The compound has also been shown to improve lipid and endothelial health through enhanced fatty-acid oxidation and reduced hepatocellular lipid accumulation, supporting healthy cholesterol and vascular function.
 It is considered a promising research candidate for studies on metabolic syndrome, type 2 diabetes, cardiovascular protection, exercise physiology, and healthy aging.
ATX-304 is available in various formulations, including 100 mg capsules (e.g., BioAmp and BioAmpMax), 150 mg capsules (PRG), 3-gram and 5-gram powder, and 30 mL liquid (100 mg/mL).
 The recommended human equivalent dose (HED) for research protocols is typically 1–3 capsules daily (100–300 mg), best taken on an empty stomach in the morning to mimic fasting-induced AMPK activation.
 The product has a shelf life of up to 36 months when stored in a cool, dry environment away from direct sunlight.